A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrentlyTechnical field
The invention belongs to TACE, post-transcatheter arterial chemoembolization (Trans Arterial Chemo Embolization) neckDomain, and in particular to a kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently.
Background technology
TACE, post-transcatheter arterial chemoembolization (Trans Arterial Chemo Embolization) is Japanese scholarsYamada was proposed first in 1997.Be applied to the treatment of liver cancer earliest, have become now mid-term more than 90% and inThe mainstream iatrotechnics formula that the hepatocarcinoma patient in later stage can select.It refers under X-ray, passes through femoral artery, abdomen master using microtubularSuppository targeting is filled into tumor focus position by artery, liver sustainer.Suppository carries out embolism resistance to supply artery of the tumorIt is disconnected, after tumor tissues blood supply is hindered so that tumour cannot grow necessary nutrition, achieve the purpose that tumour cell hungry to death.RemoveOutside this, if suppository has the function of to carry medicine, then, suppository can be released forming precisely targeting close to tumor focus annexThe effect of putting cancer therapy drug.Traditional systemic chemotherapy drug therapy is avoided for the unnecessary injury of human normal tissue.FromLiver cancer pathologic is analyzed, and hepatic tissue is by arteria hepatica and the dual blood supply of portal vein.The blood supply of normal liver tissue：75% is supplied by portal veinBlood, 25% by arteria hepatica blood supply.The blood supply of normal liver tissue and the blood supply very different of hepatic carcinoma tissue.Hepatic carcinoma tissueBlood supply 95%-99% come from arteria hepatica.Based on this species diversity, the liver of tumor locus is moved by arteria hepatica using microtubularArteries and veins carries out target administration, orients embolism.The drug concentration at tumor focus position can be so set to be higher by systemic chemotherapy 1 to 2The order of magnitude, greatly protects normal liver tissue, realizes the purpose for killing tumour cell.Certainly, because liver tumour is mostlyMultiple blood supply, therefore Arterial chemotherapy and embolization treatment can only effectively kill tumor cells of hepatocellular carcinoma in a certain range certain area, it is difficultTo realize the purpose of radical cure liver cancer.But for the hepatocarcinoma patient of middle and later periods, tumour is usually both greater than 3cm or has been above5cm, at this moment, if being capable of the development of effective symptom management, or even makes tumour progressively atrophy achievees the purpose that to extend patients ' lives,Also can yet be regarded as a kind of valuable treatment means.
In TACE art formulas, lipiodol and microballoon are most commonly used that.For the demand of low-end market, lipiodol is as a kind of liquidSuppository is cheap with its, and advantage easy to use becomes the first choice of doctor.And for the snowball of some high-end markets, carryMedicine microballoon is then because the advantage of its medicine-carried becomes development trend in TACE art formulas.Lipiodol, this liquid suppository, it is maximum the shortcomings thatIt is exactly that it cannot form permanent embolism, it can gradually be safely metabolised by the body at 1 month or so.So the blood vessel of embolism is able to againIt is logical.So often after transcatheter arterial embolization 1-2 months, patient needs embolism again.However, lipiodol is as liquid embolizing agent, itDispersivity, permeability, conduit passability are that microballoon or other embolism materials are incomparable.It can surpass choose it is very tinyVascularization embolism.And microballoon or other solid-state suppositories, it is minimum also just to block to 50 microns of blood vessels.Microballoon is as oneThe new suppository of kind.Microballoon according to material used can be divided into polyvinyl alcohol microparticles, gelatine microsphere, sodium alginate micro ball,Polylactic acid microsphere, o polyhydroxyethyl cellulose microballoon, polymethacrylate microballoon, chitosan microballoon, spherex.MicroballoonUsually there is excellent performance：Shape is regular, and size uniformity, surface is smooth, biological safety good compatibility, particleMutual bad adhesion, microballoon elastic deformability are good.And drug bearing microsphere has the chemical group of some negative electrical charges because of microsphere surface,Therefore charge interaction can be leaned on to adsorb positively charged anticancer chemotherapeutic agent.Therefore, suspension of the microballoon in physiological salineStability and transporting in microtubular are all very good, and can pinpoint target slow-release chemotherapeutics to hepatic carcinoma tissue.Drug bearing microsphere is more safe and effective as the therapeutic effect of suppository, is current most common suppository.According to the bolt in human bodyThe length of time is filled in, embolism microball can be divided into degradability microballoon and non-biodegradable microballoon.Wherein non-biodegradable microballoon boltFill in after artery can permanence, there is powerful embolism to act on, play really permanent embolism effect.Foreign countries are existing moreNon-biodegradable embolism microball that is ripe and coming into operation, such as EmboSphere microballoons, HepaShpere microballoons, BeadBlock microballoons, DC Bead microballoons, LC Bead microballoons, SAP microballoons, Embozene microballoons, Tandem microballoons etc..This is slightlyBall can embolism in the blood vessel for a long time, do not degraded by human body, therefore can always remain in patient body, form permanent embolism；AndAnd the development of most of microballoons now is individually carried out with administration, that is to say, that microballoon and contrast agent are being injected patient respectivelyAfter in vivo, the separation of microballoon and contrast agent may be caused to disconnect, so that the specific location of microballoon cannot be observed exactly.SimplySay, still also carry developing performance without a kind of microballoon so far.In addition, import microballoon is expensive, patient is difficult to bear.
The content of the invention
It is an object of the invention to overcome the shortcomings of above-mentioned technology, there is provided a kind of medicine-carried liquid embolizing agent and application thereof andPreparation method.Onyx glue is a kind of new liquid suppository, allows to inject for a long time, has more preferable dispersivity and higherThrombosis rate, autography, and have the characteristics that non-adhering.Onyx glue is generally made in the embolism of cerebral arteriovenous malformation (AVM)With.Onyx glue composition is very simple, it is by polyvinyl alcohol polyethylene and ethylene copolymers (EVOH), dimethyl sulfoxide (DMSO) (DMSO) solvent and micro-Meter level tantalum powder forms.Therefore the present invention is optimized based on original Onyx glue.By the doing of EVOH polymer in Onyx glueLearn modifying and decorating.By the chemical modification of the macromolecular chain to EVOH polymer, make macromolecular chain chemical bonding it is upper some it is cloudy fromSubbase group.These anionic groups can carry out absorption carriage to the cancer therapy drug of positively charged cationization.Retain at the same timeFormer micro-sized metal tantalum powder makes the liquid embolizing agent have developability.And original DMSO solvents will be taken by 1-methyl-2-pyrrolidinoneGeneration.The either mixed solvent of DMSO and 1-methyl-2-pyrrolidinone.By replacing solvent, it is possible to reduce the vascular toxicity of DMSO,And it is for the Metabolic stress of liver function.Generally, the amount of suppository used in peripheral blood vessel embolism is intracranial vessel embolismTwice it is even more.So DMSO is not suitable for the embolism of peripheral blood vessel.
5g EVOH polymers with 30mL 1-methyl-2-pyrrolidinones heating stirring dissolve, common sulfonating agent be the concentrated sulfuric acid,Chlorosulfonic acid, sulfur trioxide, chlorosulfuric acid etc., can make catalyst with silver sulfate sometimes, accelerate the progress of reaction.Heating stirring reacts 2-After 3 hours, room temperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to addEnter 25mlN- methyl pyrrolidones to be allowed to be redissolved, add 200ml-300mL methanol and be allowed to separate out again, be so repeated several times,Finally by drying precipitate.Or using vacuum drying.Sulfonation modifying EVOH copolymers, the N- crassitudes that will preferably obtainKetone, the mixing of Ta powder developer solutions certain proportion, stirring and dissolving, obtains liquid embolizing agent of the present invention.The load liquid bodySuppository will be provided with following characteristics：
1. product of the present invention as a kind of non-adhesive liquid embolic material there is autography to easily determine embolism starting pointAnd terminal, make embolism position more accurate.Easily by conveying microtubular, and compatible various commercially available microtubulars；
2. fluid present invention suppository main polymer has sulfonate group, therefore its cancer therapy drug with cationizationIonic interaction, is eventually exhibited as the load to cationic drug and the effect of sustained release；
3. product viscosity of the present invention is low, good biocompatibility, no cytotoxicity, controllability are good.Will not causing after embolismOr immunization, using safety；
4. 1-methyl-2-pyrrolidinone is safe as product solvent of the present invention, extra vascular destruction etc. will not be caused badReaction；
5. product embolism permeability of the present invention, dispersivity are good, embolization effect is reliable and stable.
Zoopery proves that product of the present invention is suitable for the embolotherapy of good pernicious substantial viscera tumour and bleeding lesion.Product of the present invention can be directly injected into aneurysm knurl intracavitary, adapt to the aneurysm cavity of different shape and size completely, make knurl wall and boltAny gap is not stayed between plug material, so as to achieve the purpose that permanent embolism.EVOH copolymers in the present invention, wherein polyethyleneIt is 70%-30%, preferably 60-40% that alcohol, which accounts for shared molar ratio in copolymer,.The present invention is for EVOH copolymer polyethylene alcoholThe molar ratio that part carries out anion chemical modification is classified as 40%-10%, preferably 30%-20%.Liquid embolic of the present inventionAgent, is under normal conditions liquid, is solid after blood of human body is contacted.It can be applied to treat various vascular tumors.
Embodiment
Embodiment of the specific embodiment mode below in conjunction with specific embodiment
The above of the present invention is described in further detail
Embodiment 1
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is concentrated sulfuric acid 5g,Add a little about 0.01g silver sulfates to make catalyst, accelerate the progress of reaction.After 70 degree of heating stirrings react 3 hours, room temperature is coldBut.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrrolesAlkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, Ta powder developer solutionsCertain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW01 of the present invention.
Embodiment 2
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is the concentrated sulfuric acid2.5g, adds a little about 0.01g silver sulfates to make catalyst, accelerates the progress of reaction.After 70 degree of heating stirrings react 3 hours, roomTemperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylPyrrolidones is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by sedimentIt is dry.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, the development of Ta powderAgent solution certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW02 of the present invention.(amount of sulfonation halves compared with HW01)
Embodiment 3
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is chlorosulfonic acid 5g,Add a little about 0.01g silver sulfates to make catalyst, accelerate the progress of reaction.After 70 degree of heating stirrings react 2 hours, room temperature is coldBut.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrrolesAlkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, Ta powder developer solutionsCertain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW03 of the present invention.
Embodiment 4
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is chlorosulfonic acid2.5g, adds a little about 0.01g silver sulfates to make catalyst, accelerates the progress of reaction.After 70 degree of heating stirrings react 2 hours, roomTemperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylPyrrolidones is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by sedimentIt is dry.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, the development of Ta powderAgent solution certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW04 of the present invention.
Embodiment 5
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and is acidulant with polyphosphoric acids 5g,A little about 0.1g urea is added to accelerate the progress of reaction as catalyst.After 70 degree of heating stirrings react 6 hours, room temperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methyl pyrrolidonesIt is allowed to be redissolved, adds 200ml-300mL methanol and be allowed to separate out again, be so repeated several times, finally by drying precipitate.OrUsing vacuum drying.The phosphorylation preferably obtained is modified EVOH copolymers, 1-methyl-2-pyrrolidinone, Ta powder developer solution oneCertainty ratio mixes, and stirring and dissolving, obtains liquid embolizing agent HW05 of the present invention.
Embodiment 6
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and is acidulant with concentrated nitric acid 5g, addsA little about 0.01g silver nitrates accelerate the progress of reaction as catalyst.After 70 degree of heating stirrings react 4 hours, room temperature is coldBut.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrrolesAlkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.Or using vacuum drying.It is molten that the phosphorylation preferably obtained is modified EVOH copolymers, 1-methyl-2-pyrrolidinone, Ta powder developersLiquid certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW06 of the present invention.
Derived above 6 are selected to be formulated and make contrast embolism with original Onyx and test：
The preoperative adriamycin with 150mg cationizations is formulated above to be sufficiently mixed.
The New Zealand rabbits 8, weight 2.5-3.5kg of liver cancer inductionization are selected, male and female are unlimited.Preoperative 1 fasting, it is preoperative30min intramuscular injection atropine l mg, using ketalar combination Midazolam by domestic pig general anesthesia to satisfactory state.Isolate afterwardsThigh arteria saphena is cut, and inserts 5F catheter sheaths, is intubated using 5F angiography catheter rows arteria carotis communis, injection of contrast agent row arteria carotis communisRadiography.Afterwards microtubular is surpassed to select and recommend through guiding catheter under roadmap guides and be placed on liver into arteria hepatica, microtubular head end and moveThe distal end of arteries and veins, does microtubular radiography.Product of the present invention is injected under fluoroscopic monitoring through microtubular 1-2ml syringes.By predeterminedPacket time follow-up observation, the follow-up observation time be respectively after embolism at once, 1 week, 4 weeks, 8 weeks, 12 weeks, M weeks, in follow-up observationHold for animal survival situation (diet, nervous system), check radiography, observation whether there is revascularization phenomenon；Animal is finally put to death, it is completeWhole taking-up liver carries out histology pathological examination, in observation liver vessel and surrounding change, histology pathological examination.Successful embolism has been carried out to 8 rabbits in experiment, technical difficulty, embolic processes are not run into during embolism and follow-up observationPlugging phenomenon does not occur, tube drawing is smooth.And reconfirm copolymer to different type microtubular good compatibility.After embolism withVisit observation experiment animal to survive well, diet and nerve, moving situation also occur without exception without deformity.Animal is put to deathAfter dissect, those suppository liver cancerous issues for employing anion-modified medicine-carried have different degrees of diminution.UsingThe rabbit of Onyx embolisms and the rabbit of use HW series embolisms show obvious difference.Illustrate, the chemical modification of anionReally the load for medicine and release play very positive effect.Clinical trial proves product of the present invention for good evilProperty carcinoma intervention embolism is curative for effect, safe and reliable.
The above is only some embodiments of the present invention, it is noted that for the ordinary skill people of the artFor member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also shouldIt is considered as protection scope of the present invention.